Pan-KRAS Degrading Agent Using PROTAC-Mediated Ubiquitination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRAS inhibitors, particularly those targeting KRAS G12D, face challenges due to the lack of distinct binding pockets on the KRAS protein surface and the inability of covalent binding strategies, leading to poor cell membrane permeability and limited efficacy in treating cancers with KRAS mutations.
Innovation Solution
Development of a pan-KRAS degrading agent that utilizes a compound capable of targeting KRAS G12D through protein-protein interactions, leveraging cyclic peptides with high cell uptake ability facilitated by neuropilin 1 overexpression on cancer cell membranes, and employing PROTAC technology for targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If covalent binding strategies are used to target KRAS G12C, then binding affinity is improved, but applicability to KRAS G12D is lost due to lack of cysteine residue
Solution Approach 1:
The patent employs an intermediary approach by using PROTAC technology where the compound does not directly bind to KRAS but instead recruits E3 ligases (such as CRL4^CRBN or CRL4^DDB2) as intermediaries to facilitate protein-protein interactions and induce ubiquitination. This mediator mechanism allows the compound to target KRAS G12D effectively without relying on covalent binding to cysteine residues.
Solution Approach 2:
The patent replaces the mechanical covalent binding system with a biochemical ubiquitination system. Instead of forming direct covalent bonds with KRAS cysteine residues, the compound utilizes the cellular ubiquitin-proteasome system to mark KRAS for degradation. This substitution enables targeting of KRAS G12D which lacks the necessary cysteine residue for covalent binding.
2Reliability
If small molecule inhibitors are designed to target KRAS directly, then binding specificity is improved, but cell membrane permeability deteriorates due to smooth protein surface lacking ideal binding sites
Solution Approach 1:
The patent uses PROTAC technology as an intermediary system where the compound acts as a molecular bridge between KRAS and E3 ligases. This intermediary approach allows the compound to achieve high binding specificity for KRAS G12D while maintaining cell membrane permeability, as the compound itself is a small molecule that can traverse membranes, and the specific binding event occurs intracellularly with the target protein.
3Ease of operation
If cyclic peptides with high cell uptake ability are used, then cell membrane permeability is improved, but molecular weight increases potentially reducing drug-like properties
Solution Approach 1:
The patent applies segmentation by dividing the PROTAC molecule into distinct functional modules: a KRAS G12D binding domain, a linker region, and an E3 ligase binding domain. This modular segmentation allows optimization of each component independently, enabling the design of compounds with appropriate molecular weight while maintaining cell membrane permeability through careful selection of linker length and composition.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying linker length, composition, and flexibility to optimize the balance between molecular weight and cell membrane permeability. By adjusting these parameters, the compound achieves sufficient permeability while maintaining manageable molecular weight characteristics for drug-like properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pan-KRAS degrading agent effectively inhibits KRAS G12D mutant cells in both activated and inactivated states, showing dose-dependent tumor inhibition in in vivo models of pancreatic and colorectal cancer, offering a promising therapeutic approach for KRAS-driven cancers.
Implementation Method 1
The compound induces ubiquitination of KRAS G12D and promotes its degradation
Implementation Method 2
high cell uptake ability facilitated by neuropilin 1 overexpression on cancer cell membranes
Data Source
AI summary
Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-KRAS protein, and a preparation method therefor and the use thereof as a therapeutic agent for preventing and/or treating cancers. The compound of the present invention can effectively degrade and/or inhibit the pan-KRAS protein in cells, and can be used in the preparation of a drug for treating and/or preventing relevant diseases or conditions mediated by pan-KRAS.